Legionnaires Disease

1. Disease Information

Overview

Legionnaires' disease (LD) is a severe form of pneumonia caused primarily by the Gram-negative, aerobic, facultative intracellular bacterium Legionella pneumophila (shin2026molecularevolutionand pages 2-3, cakmak2024presenceoflegionella pages 1-2). First identified during an outbreak at an American Legion convention in Philadelphia in 1976, which affected 221 people and caused 34 deaths, LD remains a significant and increasing public health threat worldwide (shin2026molecularevolutionand pages 1-2). The disease is transmitted through inhalation of contaminated aerosolized water droplets from engineered water systems such as cooling towers, hot-water distribution systems, showers, and fountains, rather than through person-to-person transmission (cakmak2024presenceoflegionella pages 1-2, yao2024areviewof pages 1-2). Although LD accounts for approximately 5% of all community-acquired pneumonia (CAP), it is one of the three most common causes of CAP requiring intensive care unit (ICU) admission (rello2024severelegionnaires’disease pages 1-3).

Key Identifiers and Classification

Table: This table summarizes core identifiers, classification terms, synonyms, and causative-agent information for Legionnaires' disease. It is useful as a compact reference for knowledge-base normalization and ontology mapping.

Synonyms and Alternative Names

Common synonyms include Legionella pneumonia, Legion fever, and legionellosis (the broader umbrella term encompassing both Legionnaires' disease and the milder, non-pneumonic Pontiac fever) (lechevallier2025thecasefor pages 2-5, shin2026molecularevolutionand pages 2-3).

2. Etiology

Causative Agent

Legionella pneumophila is the primary causative agent, responsible for approximately 90% of LD cases, with serogroup 1 (Lp1) causing over 80% of confirmed infections in Europe and the United States (shin2026molecularevolutionand pages 2-3, rello2024severelegionnaires’disease pages 1-3). Of the 61 identified Legionella species, L. longbeachae is the second most common cause of LD, particularly in Australia and New Zealand (cakmak2024presenceoflegionella pages 1-2). Nearly 50% of cases diagnosed by broader diagnostic methods are caused by non-Lp1 species or serogroups that standard urinary antigen tests cannot detect (rello2024severelegionnaires’disease pages 5-7).

L. pneumophila is a Gram-negative, facultative intracellular pathogen that naturally inhabits aquatic environments and has evolved through prolonged co-evolution with free-living amoebae such as Acanthamoeba castellanii (shin2026molecularevolutionand pages 1-2). Within these protozoan hosts, the bacterium evolved mechanisms to evade predation and replicate intracellularly, which fortuitously facilitated infection of human alveolar macrophages (shin2026molecularevolutionand pages 1-2).

Risk Factors

Environmental risk factors include: exposure to contaminated engineered water systems (cooling towers, hot tubs, fountains, plumbing networks); aging municipal water infrastructure and main line leaks; water stagnation; temperatures between 25–45°C (optimal for Legionella growth); high precipitation; elevated temperature and relative humidity (cakmak2024presenceoflegionella pages 1-2, yao2024areviewof pages 1-2, cakmak2024presenceoflegionella pages 3-5). The disease is predominantly linked to building water systems, including hospitals, hotels, and large commercial buildings (cakmak2024presenceoflegionella pages 3-5). The 2023 Poland outbreak, resulting in 14 deaths, underscored the continuing threat from inadequately maintained water systems (cakmak2024presenceoflegionella pages 1-2).

Host risk factors include: age ≥50 years; smoking history; chronic lung disease; immunosuppression (including organ transplantation, chronic corticosteroid therapy, and hematological malignancy); diabetes; chronic cardiovascular disease; and alcoholism (cakmak2024presenceoflegionella pages 2-3, rello2024severelegionnaires’disease pages 1-3). Male sex is associated with higher incidence, with an approximately 2:1 to 3:1 male-to-female ratio (rello2024severelegionnaires’disease pages 1-3).

Climatic risk factors are increasingly recognized. Temperature increases above 15°C, relative humidity above 60%, and precipitation have been significantly associated with increased LD incidence, with temperature and humidity effects most pronounced 9–10 weeks before disease onset, suggesting environmental amplification of Legionella prior to transmission (cakmak2024presenceoflegionella pages 3-5, yao2024areviewof pages 1-2).

Protective Factors

No specific genetic protective factors have been definitively established for Legionnaires' disease. Adequate water system maintenance, temperature control (maintaining hot water >55°C and cold water <25°C), and chlorine disinfection of water distribution systems are well-established environmental protective measures (yao2024areviewof pages 3-4, cakmak2024presenceoflegionella pages 2-3).

3. Phenotypes and Clinical Manifestations

Legionnaires' disease presents with a spectrum of clinical manifestations encompassing pulmonary and extrapulmonary features. The clinical presentation is often non-specific and can mimic other forms of severe pneumonia (rello2024severelegionnaires’disease pages 1-3).

Table: This table summarizes major clinical manifestations and laboratory abnormalities reported for Legionnaires’ disease, including common pneumonia features and severe extrapulmonary complications. It highlights phenotype types, approximate frequency patterns, severity, and suggested HPO mappings for knowledge base annotation.

Key Clinical Features

The hallmark of LD is severe pneumonia characterized by high fever with relative bradycardia, cough, dyspnea, and radiological findings of consolidation with surrounding ground-glass opacities (rello2024severelegionnaires’disease pages 4-5, rello2024severelegionnaires’disease pages 5-7). Diarrhea and acute confusion are frequently reported non-specific features that may suggest Legionella as the etiology (rello2024severelegionnaires’disease pages 4-5). Pontiac fever, the non-pneumonic form of legionellosis, presents with milder flu-like symptoms including fever, chills, and headache, typically resolving within 5 days of onset (shin2026molecularevolutionand pages 2-3).

Extrapulmonary Manifestations

Extrapulmonary complications are well-documented and typically result from hematogenous dissemination. These include gastrointestinal involvement (pancreatitis, colitis, liver and spleen involvement), neurological complications (encephalitis, brain abscess, cerebellar ataxia), and cardiovascular complications (myopericarditis, endocarditis) (rello2024severelegionnaires’disease pages 4-5). Rhabdomyolysis and acute kidney injury (AKI) have strong documented associations with LD; one study reported that nearly 80% of adults with L. pneumophila infection in a 10-year ICU cohort developed AKI, with half requiring renal replacement therapy (rello2024severelegionnaires’disease pages 5-7). Rare extrapulmonary forms such as lymphadenitis have also been reported (zhang2025lymphadenitiscausedby pages 3-4).

Quality of Life Impact

Severe LD requiring ICU admission (approximately one-third of cases) has profound impacts on daily functioning, with patients often requiring prolonged mechanical ventilation and hemodynamic support (rello2024severelegionnaires’disease pages 1-3). Long-term sequelae following recovery from severe LD may include persistent respiratory impairment, though specific quality-of-life instrument data (EQ-5D, SF-36) are limited in the current literature.

4. Genetic/Molecular Information

Bacterial Genomics

As an infectious disease, LD does not have specific human causal genes. Rather, the molecular pathogenesis is driven by the bacterial genome. L. pneumophila possesses a genome encoding an exceptionally large arsenal of virulence factors, including the Dot/Icm Type IVB Secretion System (T4BSS) that translocates over 300–350 effector proteins into host cells, and a Type II Secretion System (T2SS) that releases approximately 120 hydrolytic enzymes (shin2026molecularevolutionand pages 15-16, shin2026molecularevolutionand pages 1-2, lockwood2022thelegionellapneumophila pages 1-3). A comprehensive structural analysis of 368 L. pneumophila effectors identified 157 types of functional domains in 287 effectors, with 159 effectors previously lacking functional annotations and 35 unique domains with no similarity to known protein structures.

Host Genetic Susceptibility

In mouse models, the NAIP5 (Nlrc4) locus plays a critical role in innate immune defense against L. pneumophila. Wild-type mouse strains are naturally non-permissive to Legionella infection due to NAIP5-mediated recognition of bacterial flagellin, which activates the NLRC4 inflammasome and triggers pyroptotic cell death. Only macrophages from A/J mice, which are deficient in NAIP5, permit intracellular bacterial replication (rello2024severelegionnaires’disease pages 3-4). This suggests that human polymorphisms in inflammasome pathway genes could influence susceptibility, though this remains an area of active investigation.

OpenTargets Disease-Target Associations

OpenTargets identifies Legionnaires' disease under MONDO:0005824 and legionellosis under MONDO:0005823. Two drug targets are associated with legionellosis treatment at the approval stage: TOP2A (DNA topoisomerase II alpha, ENSG00000131747) and TOP2B (DNA topoisomerase II beta, ENSG00000077097), which are the targets of fluoroquinolone antibiotics used in LD treatment (OpenTargets Search: Legionnaires disease,legionellosis).

5. Environmental Information

Environmental Sources

L. pneumophila naturally inhabits aquatic environments but proliferates in engineered water systems. Major sources include cooling towers, hot water distribution systems, decorative fountains, swimming pools, hot tubs, and humidifiers (cakmak2024presenceoflegionella pages 1-2, cakmak2024presenceoflegionella pages 3-5, yao2024areviewof pages 2-3). The bacterium survives within biofilms that confer resistance to sterilizing chemicals, thrives at temperatures between 25–45°C, and requires specific nutrients including amino acids and ferric ions (cakmak2024presenceoflegionella pages 3-5). Water stagnation promotes bacterial proliferation (cakmak2024presenceoflegionella pages 3-5).

Climate Influence

Climate variables significantly influence LD incidence. Temperature increases above 15°C showed an incidence rate ratio of 1.45 (95% CI: 1.33–1.58) for each 5°C increase, with a lag of 10–9 weeks before onset. Relative humidity above 60% (IRR = 1.19, 95% CI: 1.12–1.26 per 5% increase) and precipitation (IRR = 1.07, 95% CI: 1.06–1.09 per 5 mm increase above 10 mm, 1-week lag) also significantly increase risk (cakmak2024presenceoflegionella pages 3-5). Precipitation has emerged as a strong driver of sporadic community-acquired cases in the United States, while temperature and relative humidity are moderate drivers (cakmak2024presenceoflegionella pages 3-5, yao2024areviewof pages 1-2).

Infectious Agent Classification

• Organism: Legionella pneumophila (NCBI Taxonomy ID: 446)
• Classification: Gram-negative, aerobic, rod-shaped bacterium; Family Legionellaceae; Order Legionellales
• Key species: L. pneumophila (dominant pathogen), L. longbeachae, L. sainthelensi, and 58+ other species (cakmak2024presenceoflegionella pages 1-2, zhang2025lymphadenitiscausedby pages 3-4)

6. Mechanism / Pathophysiology

Intracellular Infection Cycle

The pathophysiology of LD centers on the bacterium's ability to replicate within human alveolar macrophages. Upon inhalation of contaminated aerosols, L. pneumophila is phagocytosed by alveolar macrophages, where it immediately deploys the Dot/Icm T4BSS to deliver over 300 effector proteins into the host cytosol (shin2026molecularevolutionand pages 15-16, lockwood2022thelegionellapneumophila pages 1-3). These effectors manipulate host vesicle trafficking and endomembrane dynamics to prevent phagosome-lysosome fusion, instead remodeling the phagocytic vacuole into an endoplasmic reticulum (ER)-derived compartment known as the Legionella-containing vacuole (LCV) (shin2026molecularevolutionand pages 1-2, lockwood2022thelegionellapneumophila pages 1-3).

Key Molecular Pathways

Vesicle trafficking manipulation: Effector proteins such as SidC contain phosphatidylinositol 4-phosphate (PI(4)P)-specific binding domains essential for targeting to the bacterial phagosome. VipD interferes with host endosomal trafficking by targeting Rab GTPases (shin2026molecularevolutionand pages 22-22). LidA is a characterized Dot/Icm substrate involved in maintaining bacterial integrity within the LCV (shin2026molecularevolutionand pages 18-19).

Autophagy inhibition: The effector RavZ cleaves LC3 (Atg8) to block autophagosome maturation, preventing autophagic destruction of the bacteria (shin2026molecularevolutionand pages 14-15, shin2026molecularevolutionand pages 18-19). GO terms: autophagy (GO:0006914), negative regulation of autophagy (GO:0010507).

Host translation modulation: Multiple effectors including SidI, SidL, LegK4, and Lgt family members inhibit host protein translation by targeting elongation factors and ribosomes, while others (LegA9, LegC4, LamA) counteract this blockade to promote production of specific inflammatory cytokines (shin2026molecularevolutionand pages 12-14, shin2026molecularevolutionand pages 14-15).

Mitochondrial manipulation: Effectors Lpg0080 and Lpg0081 function as ADP-ribosyl transferases that modify mitochondrial ADP/ATP translocases to suppress energy-dependent autophagy signals (shin2026molecularevolutionand pages 14-15, shin2026molecularevolutionand pages 12-14).

Nutrient acquisition: The conserved core effector MavN scavenges iron from the host cell, which is essential for bacterial growth within the LCV; iron limitation triggers growth arrest and host cell exit (lockwood2022thelegionellapneumophila pages 26-28). LppA degrades phytate to overcome nutritional restriction (lockwood2022thelegionellapneumophila pages 26-28). GO terms: iron ion transport (GO:0006826), siderophore-dependent iron import into cell (GO:0048238).

Immune Response

Inflammasome activation: Bacterial flagellin is sensed by Naip5, which complexes with NLRC4 to activate the inflammasome in a Dot/Icm-dependent manner, triggering caspase-1 activation and pyroptotic cell death (shin2026molecularevolutionand pages 12-14). GO terms: inflammasome complex (GO:0061702), pyroptosis (GO:0070269).

Differential cell-type responses: Macrophages and dendritic cells (DCs) respond distinctly to L. pneumophila. In macrophages, the bacterium establishes robust intracellular replication, while DCs undergo rapid cell death through two mechanisms: early caspase-11 and NLRP3 inflammasome-dependent pyroptosis, and later effector-triggered apoptosis driven by T4SS effector-mediated blockade of host protein synthesis (depleting pro-survival proteins Mcl-1 and cFLIP) (shin2026molecularevolutionand pages 12-14).

Epigenetic reprogramming: L. pneumophila modulates macrophage functions through epigenetic reprogramming via the C-type lectin receptor Mincle, representing a novel mechanism of host cell manipulation.

Tissue damage: Replication of L. pneumophila within macrophages and monocytes triggers a hyperactive inflammatory response that damages lung tissue, resulting in the severe pneumonia characteristic of LD (cakmak2024presenceoflegionella pages 2-3). Host cell exit during late infection involves heterogeneous transition from replicative to transmissive forms, with the bacterium producing flagella and secreting phospholipases (PlaA, PlaB, PlaD, PlcC) to lyse the LCV and host cell (lockwood2022thelegionellapneumophila pages 26-28).

Cell Types Involved

• Alveolar macrophages (CL:0000583) — primary target and replicative niche
• Dendritic cells (CL:0000451) — activate pyroptosis and restrict infection
• Neutrophils (CL:0000775) — essential for early innate immune control
• Monocytes (CL:0000576) — recruited during infection

7. Anatomical Structures Affected

Organ Level

• Primary: Lungs (UBERON:0002048) — site of primary infection and pneumonia
• Secondary: Kidneys (UBERON:0002113) — AKI in up to 80% of ICU cases; liver (UBERON:0002107); spleen; gastrointestinal tract (UBERON:0005409); central nervous system (UBERON:0001017); heart (UBERON:0000948) — myocarditis/pericarditis (rello2024severelegionnaires’disease pages 4-5, rello2024severelegionnaires’disease pages 5-7)
• Body systems: Respiratory, renal, gastrointestinal, neurological, cardiovascular (rello2024severelegionnaires’disease pages 4-5)

Tissue and Cell Level

• Pulmonary alveolar epithelium — site of initial aerosol deposition
• Alveolar macrophages (CL:0000583) — primary intracellular replicative niche
• Lung interstitium — inflammatory infiltrate and tissue damage

Subcellular Level

• Legionella-containing vacuole (LCV) — ER-derived compartment (GO:0005783 — endoplasmic reticulum)
• Mitochondria (GO:0005739) — targeted by effectors for metabolic manipulation
• Endosomes/lysosomes (GO:0005764) — phagosome-lysosome fusion is inhibited

8. Temporal Development

Onset

• Incubation period: 2–10 days after exposure for Legionnaires' disease; 5–72 hours for Pontiac fever (shin2026molecularevolutionand pages 2-3)
• Onset pattern: Acute; symptoms develop rapidly following incubation
• Typical age of onset: Adult and geriatric populations; highest burden in individuals >70 years (zhong2025theglobalburden pages 1-2, zhong2025theglobalburden pages 6-8)

Progression

• LD can progress rapidly from initial pneumonia to respiratory failure, septic shock, and multi-organ dysfunction
• ICU admission occurs in approximately one-third of cases (rello2024severelegionnaires’disease pages 1-3)
• Disease duration is typically 2–6 weeks with appropriate treatment; prolonged in severe and immunocompromised cases (zhang2025lymphadenitiscausedby pages 4-6)
• Pontiac fever is self-limited, resolving within 5 days (shin2026molecularevolutionand pages 2-3)

9. Inheritance and Population

Epidemiology

Table: This table summarizes the most relevant recent epidemiology and global burden metrics for Legionnaires' disease, including incidence, mortality, healthcare burden, and age-stratified risk. It is useful as a compact reference for disease knowledge base population and comparative public health assessment.

The global burden of Legionella-associated diseases has shifted significantly over the 1990–2021 period, with the overall age-standardized DALY and death rates declining (EAPC: −1.42% and −0.75%, respectively), but with concerning upward trends in specific age groups (15–49 years: EAPC 0.43% for DALYs; 50–69 years: EAPC 0.14%) (zhong2025theglobalburden pages 1-2, zhong2025theglobalburden pages 2-4). Sub-Saharan Africa carries the highest regional burden, while high-income regions have the lowest (zhong2025theglobalburden pages 2-4).

In the EU/EEA, LD notification rates increased from 1.2–1.4 per 100,000 population in 2012–2016 to 1.8–2.2 per 100,000 in 2017–2019, representing a 33.9% increase above predicted levels (cakmak2024presenceoflegionella pages 3-5). In the United States, the estimated 52,000–70,000 annual cases represent a more than five-fold increase since the early 2000s, with Legionella being the leading cause of waterborne disease outbreaks, responsible for 43% of outbreaks and 94% of hospitalizations (cakmak2024presenceoflegionella pages 3-5). The reported incidence increased 249% between 2000 and 2011 (shin2026molecularevolutionand pages 2-3).

Population Demographics

• Age distribution: Highest burden in individuals >70 years (101.85 ASR-DALYs per 100,000 in 2021) (zhong2025theglobalburden pages 1-2)
• Sex ratio: Male predominance, approximately 2:1 to 3:1 (rello2024severelegionnaires’disease pages 1-3)
• Racial and socioeconomic disparities: In the US, poverty level was the strongest risk factor for legionellosis in multivariate models; racial and socioeconomic inequities are largely understudied but emerging as important drivers (cakmak2024presenceoflegionella pages 3-5)
• Seasonal patterns: Clear seasonality with trough in early spring and peak in autumn (peak-to-trough ratio = 3.62) (cakmak2024presenceoflegionella pages 3-5)

10. Diagnostics

Clinical Tests

Table: This table summarizes the major diagnostic methods for Legionnaires' disease, including performance characteristics, turnaround times, and practical strengths and limitations. It is useful for comparing rapid clinical tests with confirmatory and environmental methods.

Urinary antigen test (UAT) is the most widely used first-line diagnostic, detecting L. pneumophila serogroup 1 antigen with 70–90% sensitivity and nearly 100% specificity, with results available in 15–30 minutes (rello2024severelegionnaires’disease pages 5-7). However, UAT misses non-serogroup 1 and non-pneumophila species, significantly underestimating true LD incidence (rello2024severelegionnaires’disease pages 5-7, shin2026molecularevolutionand pages 2-3).

PCR from respiratory specimens (BAL or sputum) offers superior sensitivity (96.8–97.7%) and can detect all Legionella species and serogroups (rello2024severelegionnaires’disease pages 5-7). Nucleic acid-based testing increases detection of non-pneumophila serogroup 1 species compared to non-NAT methods (rello2024severelegionnaires’disease pages 5-7).

Culture on buffered charcoal yeast extract (BCYE) agar remains the gold standard with 100% specificity but only 50–80% sensitivity, requiring days to weeks for results (zhang2025lymphadenitiscausedby pages 3-4, cakmak2024presenceoflegionella pages 5-6).

Next-generation sequencing (NGS) is emerging as a highly sensitive method capable of simultaneously identifying multiple pathogens with low pathogen load requirements (zhang2025lymphadenitiscausedby pages 3-4, zhang2025lymphadenitiscausedby pages 4-6).

Imaging

Chest radiography and CT scanning show consolidations that are typically larger than expected, surrounded by ground-glass opacities, and can progress from patchy infiltrates to bilateral interstitial pneumonia (rello2024severelegionnaires’disease pages 4-5, rello2024severelegionnaires’disease pages 5-7).

Laboratory Abnormalities

Common findings include hyponatremia, elevated creatine kinase, impaired renal function, hyperleukocytosis with lymphopenia, and elevated C-reactive protein (rello2024severelegionnaires’disease pages 4-5).

Differential Diagnosis

Other causes of severe community-acquired pneumonia including Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, influenza virus, and other atypical pneumonia pathogens must be considered (rello2024severelegionnaires’disease pages 1-3).

11. Outcome/Prognosis

Mortality

Overall mortality of LD ranges from 7–10%, though estimates vary from 4% to 40% depending on clinical setting (cakmak2024presenceoflegionella pages 1-2, rello2024severelegionnaires’disease pages 1-3). Fatality rate is approximately 10% in otherwise healthy individuals and exceeds 25% in high-risk patients including the elderly, smokers, and immunocompromised individuals (shin2026molecularevolutionand pages 2-3). Mortality in ICU patients, immunocompromised patients, or those with nosocomial infection can reach 40% despite appropriate antimicrobial therapy (rello2024severelegionnaires’disease pages 1-3).

Complications

Major complications include acute respiratory distress syndrome, septic shock, and acute renal failure. Nearly 80% of ICU patients with L. pneumophila developed AKI in one 10-year cohort, with approximately half requiring renal replacement therapy (rello2024severelegionnaires’disease pages 5-7, rello2024severelegionnaires’disease pages 1-3). Rhabdomyolysis and extrapulmonary dissemination to the liver, spleen, gastrointestinal tract, nervous system, and cardiovascular system are well-documented complications (rello2024severelegionnaires’disease pages 4-5).

Prognostic Factors

Factors influencing mortality include ICU admission requirement, underlying immune status, nosocomial versus community acquisition, timing of appropriate antimicrobial therapy, and the host immune response (hyperinflammation and/or immunoparalysis) (rello2024severelegionnaires’disease pages 1-3). Early antibiotic therapy within 24 hours of hospital admission with macrolides or levofloxacin is protective against clinical deterioration and ICU admission (rello2024severelegionnaires’disease pages 5-7).

12. Treatment

Pharmacotherapy

First-line agents: Treatment is based on macrolides (azithromycin), fluoroquinolones (levofloxacin, moxifloxacin), or a combination of both, as recommended by IDSA guidelines (rello2024severelegionnaires’disease pages 5-7, rello2024severelegionnaires’disease pages 1-3). MAXO terms: MAXO:0000058 (antimicrobial treatment).

• Azithromycin: Commonly administered at 0.5 g daily, initially intravenous for 2 weeks followed by 2 weeks oral in severe cases (zhang2025lymphadenitiscausedby pages 3-4)
• Fluoroquinolones: Levofloxacin is widely used; fluoroquinolones target bacterial DNA topoisomerase II (TOP2A/TOP2B) (OpenTargets Search: Legionnaires disease,legionellosis)
• β-lactam and aminoglycoside antibiotics are ineffective against Legionella due to poor cell membrane penetration and inability to reach intracellular bacteria (zhang2025lymphadenitiscausedby pages 3-4, zhang2025lymphadenitiscausedby pages 4-6)

Treatment duration: 2 weeks for immunocompetent hosts; 3 weeks for immunosuppressed patients; prolonged treatment in severe cases (zhang2025lymphadenitiscausedby pages 4-6).

Alternative agents: Effective alternatives include doxycycline, tigecycline, cotrimoxazole, and rifampicin (zhang2025lymphadenitiscausedby pages 4-6). Omadacycline, a newer tetracycline antibiotic, has been highlighted as an effective option with good lung tissue penetration, particularly suitable for patients with quinolone intolerance or hepatic/renal impairment (cakmak2024presenceoflegionella pages 5-6).

Supportive Care

Severe cases require respiratory support including mechanical ventilation, hemodynamic support with vasoactive agents, and renal replacement therapy for AKI (rello2024severelegionnaires’disease pages 5-7, rello2024severelegionnaires’disease pages 1-3). MAXO terms: MAXO:0000756 (mechanical ventilation), MAXO:0001174 (renal replacement therapy).

Clinical Trials

Several clinical studies have addressed LD diagnostics and management: - NCT03064737: Bacterial and human biomarkers of prognostic value for severe Legionnaire's disease (Hospices Civils de Lyon; 300 participants) (NCT00452153 chunk 1) - NCT00452153: Evaluation of Legionella PCR techniques for routine diagnosis (Centre Hospitalier Universitaire de Saint Etienne; 200 participants) (NCT00452153 chunk 1) - NCT07352462: Volatile organic compounds analysis for respiratory infection diagnosis (not yet recruiting; 777 participants)

13. Prevention

Primary Prevention

Water management programs are the cornerstone of LD prevention. The WHO recommends implementing water safety plans based on HACCP (Hazard Analysis and Critical Control Points) principles to identify and manage risks in building water systems (yao2024areviewof pages 4-5). These plans should guide construction, design, routine monitoring, and management of water systems in hospitals, long-term care facilities, spas, and hotels (yao2024areviewof pages 4-5).

Temperature control is the most effective primary prevention measure: - Hot water systems should maintain circulating water above 55°C (yao2024areviewof pages 3-4, yao2024areviewof pages 2-3, yao2024areviewof pages 11-11) - Cold water should be kept below 25°C (yao2024areviewof pages 3-4) - Thermal disinfection (raising water to 65°C) has successfully contained outbreaks (yao2024areviewof pages 4-5) - L. pneumophila thrives at 25–45°C but is killed at temperatures >60°C (cakmak2024presenceoflegionella pages 3-5)

Water disinfection: Maintenance of free chlorine levels (0.2–4.0 mg/L) throughout distribution systems is required under the US Safe Drinking Water Act (cakmak2024presenceoflegionella pages 2-3). Regular cleaning and disinfection of cooling towers, fountains, and other water features are essential (yao2024areviewof pages 2-3).

Regulatory frameworks: Multiple countries have implemented standards for Legionella monitoring and control. Australia's AS/NZS 3666:2011 specifies minimum requirements for air and water supply system management. China implemented comprehensive standards in 2023–2024 addressing monitoring and hygienic management of central air conditioning systems (yao2024areviewof pages 7-8). MAXO terms: MAXO:0000486 (environmental intervention).

Secondary Prevention

Environmental monitoring: Routine water sampling from water tanks, air conditioning systems, shower heads, faucets, and thermal pools enables early detection of contamination sources (cakmak2024presenceoflegionella pages 2-3). Monitoring for L. pneumophila specifically (rather than all Legionella species) has been recommended for public water systems, as it is the overwhelming cause of illness and has simple analytical methods (lechevallier2025thecasefor pages 2-5).

Surveillance systems: Established surveillance networks enable detection of epidemiological trends and timely intervention, including the European Surveillance System (TESSy) and European Working Group for Legionella Infections (EWGLI) guidelines for travel-associated LD (yao2024areviewof pages 11-11).

Immunization

No vaccine is currently available for Legionnaires' disease. Vaccine development remains an area of ongoing research.

14. Other Species / Natural Disease

Taxonomy and Environmental Hosts

L. pneumophila (NCBI Taxonomy ID: 446) naturally parasitizes free-living amoebae in aquatic environments, including Acanthamoeba castellanii and Dictyostelium discoideum (torresescobar2024anutritionalimmunity pages 30-32, schmidt2024theuniquelegionella pages 21-23). The bacterium has co-evolved with these protozoan hosts over evolutionary timescales, developing mechanisms for intracellular survival that proved transferable to human alveolar macrophages (shin2026molecularevolutionand pages 1-2).

Zoonotic and Cross-Species Considerations

LD is not a zoonotic disease in the traditional sense — humans are considered accidental hosts who become infected through exposure to environmental Legionella rather than through animal-to-human transmission (yao2024areviewof pages 1-2). Guinea pigs are naturally susceptible to L. pneumophila infection and develop pneumonia similar to human disease, while most wild-type mouse strains are naturally resistant (shin2026molecularevolutionand pages 2-3, rello2024severelegionnaires’disease pages 3-4).

15. Model Organisms

Animal Models

Mouse models: Murine models are the most commonly used for studying anti-Legionella immune responses, but wild-type mice are naturally non-permissive to infection due to NAIP5-mediated inflammasome activation (rello2024severelegionnaires’disease pages 3-4). A/J mice, which are deficient in NAIP5, permit intracellular bacterial replication and are used as a permissive model. C57BL/6 mice are used for survival and CFU experiments via intranasal or intratracheal inoculation (schmidt2024theuniquelegionella pages 21-23, rello2024severelegionnaires’disease pages 3-4).

Guinea pig models: Guinea pigs are naturally susceptible and develop pneumonia resembling human LD, making them valuable for studying early inflammatory events during experimental pneumonia (torresescobar2024anutritionalimmunity pages 30-32, shin2026molecularevolutionand pages 2-3).

Protozoan Models

Acanthamoeba castellanii: Used extensively to study intracellular replication, virulence factor function, and host-pathogen dynamics. Represents the natural environmental host (torresescobar2024anutritionalimmunity pages 30-32, schmidt2024theuniquelegionella pages 21-23).

Dictyostelium discoideum: Employed as a genetically tractable model for studying host-pathogen interactions and genetic analysis of bacterial virulence determinants (torresescobar2024anutritionalimmunity pages 30-32).

Cell Line and Primary Cell Models

• THP-1 cells: Human monocytic cell line differentiated into macrophage-like cells for infection studies (schmidt2024theuniquelegionella pages 17-18, schmidt2024theuniquelegionella pages 21-23)
• Bone marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs): From C57BL/6 or A/J mice for studying innate immune responses
• Human monocyte-derived macrophages (hMDMs): Primary human cells for translational studies (schmidt2024theuniquelegionella pages 17-18)
• U2OS cells: Human osteosarcoma epithelial cells for studying intracellular bacterial effector functions (schmidt2024theuniquelegionella pages 21-23)

Model Limitations

A key limitation of mouse models is that wild-type strains resist L. pneumophila infection, requiring the use of NAIP5-deficient strains that do not fully recapitulate the human immune response. Guinea pig models more closely recapitulate human disease but are less amenable to genetic manipulation (shin2026molecularevolutionand pages 2-3, rello2024severelegionnaires’disease pages 3-4). Transposon sequencing approaches in animal models are complicated by the suboptimal nature of available L. pneumophila infection models for conventional saturated mutant library screens.

Summary

Legionnaires' disease is a severe, increasingly prevalent waterborne pneumonia caused by the facultative intracellular pathogen Legionella pneumophila. The disease burden is rising globally, driven by aging populations, increasing immunosuppression, climate change, aging water infrastructure, and improved diagnostic detection (rello2024severelegionnaires’disease pages 1-3, cakmak2024presenceoflegionella pages 3-5, zhong2025theglobalburden pages 1-2). The pathophysiology centers on the extraordinary Dot/Icm Type IV Secretion System, which delivers over 300 effector proteins to manipulate host cell processes including vesicle trafficking, autophagy, translation, and metabolism (shin2026molecularevolutionand pages 15-16, shin2026molecularevolutionand pages 1-2, lockwood2022thelegionellapneumophila pages 1-3). While diagnostic capabilities have improved with UAT and PCR-based methods, the true epidemiological burden remains underestimated due to diagnostic limitations and under-testing (rello2024severelegionnaires’disease pages 5-7, shin2026molecularevolutionand pages 2-3). Treatment relies on macrolides and fluoroquinolones, and prevention strategies focus on comprehensive water management programs with temperature control and disinfection (rello2024severelegionnaires’disease pages 5-7, yao2024areviewof pages 3-4, yao2024areviewof pages 4-5). Future priorities include development of broader diagnostic tests, identification of severity biomarkers, evaluation of host-directed therapies, and enhanced public health surveillance to address the rising global burden of this important infectious disease (rello2024severelegionnaires’disease pages 1-3).

References

1. (shin2026molecularevolutionand pages 2-3): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

2. (cakmak2024presenceoflegionella pages 1-2): Ömer Çakmak, Tuba Aldemir, Erdi Ergene, Ulaş Acaröz, Damla Arslan-acaroz, and Nuri Taş. Presence of legionella pneumophila in tap water and its importance for public health. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni, 15:64-76, Aug 2024. URL: https://doi.org/10.38137/vftd.1432171, doi:10.38137/vftd.1432171. This article has 1 citations.

3. (shin2026molecularevolutionand pages 1-2): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

4. (yao2024areviewof pages 1-2): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

5. (rello2024severelegionnaires’disease pages 1-3): Jordi Rello, Camille Allam, Alfonsina Ruiz-Spinelli, and Sophie Jarraud. Severe legionnaires’ disease. Annals of Intensive Care, Apr 2024. URL: https://doi.org/10.1186/s13613-024-01252-y, doi:10.1186/s13613-024-01252-y. This article has 85 citations and is from a peer-reviewed journal.

6. (lechevallier2025thecasefor pages 2-5): Mark W. LeChevallier. The case for monitoring for legionella pneumophila in drinking water distribution systems. Water, 17:475, Feb 2025. URL: https://doi.org/10.3390/w17040475, doi:10.3390/w17040475. This article has 8 citations.

7. (OpenTargets Search: Legionnaires disease,legionellosis): Open Targets Query (Legionnaires disease,legionellosis, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (rello2024severelegionnaires’disease pages 5-7): Jordi Rello, Camille Allam, Alfonsina Ruiz-Spinelli, and Sophie Jarraud. Severe legionnaires’ disease. Annals of Intensive Care, Apr 2024. URL: https://doi.org/10.1186/s13613-024-01252-y, doi:10.1186/s13613-024-01252-y. This article has 85 citations and is from a peer-reviewed journal.

9. (yao2024areviewof pages 2-3): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

10. (cakmak2024presenceoflegionella pages 2-3): Ömer Çakmak, Tuba Aldemir, Erdi Ergene, Ulaş Acaröz, Damla Arslan-acaroz, and Nuri Taş. Presence of legionella pneumophila in tap water and its importance for public health. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni, 15:64-76, Aug 2024. URL: https://doi.org/10.38137/vftd.1432171, doi:10.38137/vftd.1432171. This article has 1 citations.

11. (shin2026molecularevolutionand pages 15-16): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

12. (lockwood2022thelegionellapneumophila pages 1-3): Daniel C. Lockwood, Himani Amin, Tiago R. D. Costa, and Gunnar N. Schroeder. The legionella pneumophila dot/icm type iv secretion system and its effectors. May 2022. URL: https://doi.org/10.1099/mic.0.001187, doi:10.1099/mic.0.001187. This article has 64 citations and is from a peer-reviewed journal.

13. (cakmak2024presenceoflegionella pages 3-5): Ömer Çakmak, Tuba Aldemir, Erdi Ergene, Ulaş Acaröz, Damla Arslan-acaroz, and Nuri Taş. Presence of legionella pneumophila in tap water and its importance for public health. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni, 15:64-76, Aug 2024. URL: https://doi.org/10.38137/vftd.1432171, doi:10.38137/vftd.1432171. This article has 1 citations.

14. (yao2024areviewof pages 3-4): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

15. (rello2024severelegionnaires’disease pages 4-5): Jordi Rello, Camille Allam, Alfonsina Ruiz-Spinelli, and Sophie Jarraud. Severe legionnaires’ disease. Annals of Intensive Care, Apr 2024. URL: https://doi.org/10.1186/s13613-024-01252-y, doi:10.1186/s13613-024-01252-y. This article has 85 citations and is from a peer-reviewed journal.

16. (zhang2025lymphadenitiscausedby pages 3-4): Cangjian Zhang and Minlei Zhao. Lymphadenitis caused by legionella sainthelensi infection: a case report and literature review. Frontiers in Medicine, May 2025. URL: https://doi.org/10.3389/fmed.2025.1574205, doi:10.3389/fmed.2025.1574205. This article has 2 citations.

17. (rello2024severelegionnaires’disease pages 3-4): Jordi Rello, Camille Allam, Alfonsina Ruiz-Spinelli, and Sophie Jarraud. Severe legionnaires’ disease. Annals of Intensive Care, Apr 2024. URL: https://doi.org/10.1186/s13613-024-01252-y, doi:10.1186/s13613-024-01252-y. This article has 85 citations and is from a peer-reviewed journal.

18. (shin2026molecularevolutionand pages 22-22): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

19. (shin2026molecularevolutionand pages 18-19): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

20. (shin2026molecularevolutionand pages 14-15): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

21. (shin2026molecularevolutionand pages 12-14): Cheon Jee Shin and Yousef Abu Kwaik. Molecular evolution and adaptations of legionella pneumophila from amoebae hosts to macrophages. Frontiers in Cellular and Infection Microbiology, Feb 2026. URL: https://doi.org/10.3389/fcimb.2026.1787137, doi:10.3389/fcimb.2026.1787137. This article has 0 citations.

22. (lockwood2022thelegionellapneumophila pages 26-28): Daniel C. Lockwood, Himani Amin, Tiago R. D. Costa, and Gunnar N. Schroeder. The legionella pneumophila dot/icm type iv secretion system and its effectors. May 2022. URL: https://doi.org/10.1099/mic.0.001187, doi:10.1099/mic.0.001187. This article has 64 citations and is from a peer-reviewed journal.

23. (zhong2025theglobalburden pages 1-2): Yonghong Zhong, Linfeng Shen, Yan Zhou, Yibo Sun, Xiaofang Fu, and Huaqiong Huang. The global burden and trends of legionella spp. infection-associated diseases from 1990 to 2021: an observational study. Journal of Epidemiology and Global Health, Jan 2025. URL: https://doi.org/10.1007/s44197-025-00342-9, doi:10.1007/s44197-025-00342-9. This article has 13 citations and is from a peer-reviewed journal.

24. (zhong2025theglobalburden pages 6-8): Yonghong Zhong, Linfeng Shen, Yan Zhou, Yibo Sun, Xiaofang Fu, and Huaqiong Huang. The global burden and trends of legionella spp. infection-associated diseases from 1990 to 2021: an observational study. Journal of Epidemiology and Global Health, Jan 2025. URL: https://doi.org/10.1007/s44197-025-00342-9, doi:10.1007/s44197-025-00342-9. This article has 13 citations and is from a peer-reviewed journal.

25. (zhang2025lymphadenitiscausedby pages 4-6): Cangjian Zhang and Minlei Zhao. Lymphadenitis caused by legionella sainthelensi infection: a case report and literature review. Frontiers in Medicine, May 2025. URL: https://doi.org/10.3389/fmed.2025.1574205, doi:10.3389/fmed.2025.1574205. This article has 2 citations.

26. (zhong2025theglobalburden pages 2-4): Yonghong Zhong, Linfeng Shen, Yan Zhou, Yibo Sun, Xiaofang Fu, and Huaqiong Huang. The global burden and trends of legionella spp. infection-associated diseases from 1990 to 2021: an observational study. Journal of Epidemiology and Global Health, Jan 2025. URL: https://doi.org/10.1007/s44197-025-00342-9, doi:10.1007/s44197-025-00342-9. This article has 13 citations and is from a peer-reviewed journal.

27. (NCT00452153 chunk 1): Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis. Centre Hospitalier Universitaire de Saint Etienne. 2007. ClinicalTrials.gov Identifier: NCT00452153

28. (cakmak2024presenceoflegionella pages 5-6): Ömer Çakmak, Tuba Aldemir, Erdi Ergene, Ulaş Acaröz, Damla Arslan-acaroz, and Nuri Taş. Presence of legionella pneumophila in tap water and its importance for public health. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni, 15:64-76, Aug 2024. URL: https://doi.org/10.38137/vftd.1432171, doi:10.38137/vftd.1432171. This article has 1 citations.

29. (yao2024areviewof pages 4-5): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

30. (yao2024areviewof pages 11-11): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

31. (yao2024areviewof pages 7-8): Xiao Hui Yao, Fan Shen, Jing Hao, Lu Huang, and Bin Keng. A review of legionella transmission risk in built environments: sources, regulations, sampling, and detection. Frontiers in Public Health, Jul 2024. URL: https://doi.org/10.3389/fpubh.2024.1415157, doi:10.3389/fpubh.2024.1415157. This article has 31 citations.

32. (torresescobar2024anutritionalimmunity pages 30-32): Ascención Torres-Escobar, Ashley Wilkins, María D Juárez-Rodríguez, Magdalena Circu, Brian Latimer, Ana-Maria Dragoi, and Stanimir S. Ivanov. A nutritional immunity blockade controls extracellular bacterial replication in legionella pneumophila infections. bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.21.576562, doi:10.1101/2024.01.21.576562. This article has 1 citations.

33. (schmidt2024theuniquelegionella pages 21-23): Silke Schmidt, Sonia Mondino, Laura Gomez-Valero, Pedro Escoll, Danielle P. A. Mascarenhas, Augusto Gonçalves, Pedro H. M. Camara, Francisco J. Garcia Rodriguez, Christophe Rusniok, Martin Sachse, Maryse Moya-Nilges, Thierry Fontaine, Dario S. Zamboni, and Carmen Buchrieser. The unique legionella longbeachae capsule favors intracellular replication and immune evasion. Sep 2024. URL: https://doi.org/10.1371/journal.ppat.1012534, doi:10.1371/journal.ppat.1012534. This article has 6 citations and is from a highest quality peer-reviewed journal.

34. (schmidt2024theuniquelegionella pages 17-18): Silke Schmidt, Sonia Mondino, Laura Gomez-Valero, Pedro Escoll, Danielle P. A. Mascarenhas, Augusto Gonçalves, Pedro H. M. Camara, Francisco J. Garcia Rodriguez, Christophe Rusniok, Martin Sachse, Maryse Moya-Nilges, Thierry Fontaine, Dario S. Zamboni, and Carmen Buchrieser. The unique legionella longbeachae capsule favors intracellular replication and immune evasion. Sep 2024. URL: https://doi.org/10.1371/journal.ppat.1012534, doi:10.1371/journal.ppat.1012534. This article has 6 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03